Drug development in Alzheimer's disease: darkness before the dawn?

Wed3  Sep09:15am(45 mins)
Charter 4
Keynote Speaker:


With an increasingly elderly population, the prevalence of Alzheimer’s disease (AD) is set to increase dramatically. Given the cost and complexity of caring for patients with dementia, there is an urgent need for medicines or other interventions that delay, or deflect the course of the disease. Despite many attempts, no disease-modifying drug has yet met its primary outcome measures for AD. There is much to be learned by reviewing what we know about the temporal course of Alzheimer’s disease, the interplay of the major pathologies, and the preclinical to clinical translation of potential AD therapeutics.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021